Annual report pursuant to Section 13 and 15(d)

Research and Development Agreements (Tables)

v3.22.1
Research and Development Agreements (Tables)
12 Months Ended
Dec. 31, 2021
Schedule of Research and Development Revenues Disaggregated by Location

Research and Development revenue is attributable to regions based on the location of our collaboration partner's parent company headquarters. Research and Development revenues disaggregated by location were as follows (in thousands):

 

 

 

Year Ended

December 31,

 

 

 

2021

 

 

2020

 

Japan

 

$

13,136

 

 

$

6,567

 

United States

 

 

25,561

 

 

 

9,068

 

Total research and development revenue

 

$

38,697

 

 

$

15,635

 

 

Millennium Pharmaceuticals Inc  
Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements

Research and development revenue from related party relates to revenue from research and development agreements with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda and were as follows (in thousands):

 

 

 

Year Ended

December 31,

 

 

 

2021

 

 

2020

 

Takeda Development and License Agreement

 

$

13,114

 

 

$

6,068

 

Takeda Multi-Target Agreement

 

 

22

 

 

 

499

 

Total research and development revenue, related party

 

$

13,136

 

 

$

6,567

 

 

Takeda Pharmaceuticals Inc  
Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from Research and Development Agreements

At December 31, 2021 and December 31, 2020, the Company had deferred revenue, other liabilities for co-share payments and accounts receivable balances from the research and development agreements with Takeda, who is a related party. These amounts were as follows (in thousands):  

 

 

December 31, 2021

 

 

December 31, 2020

 

Assets

 

 

 

 

 

 

 

 

Accounts receivable

 

$

 

 

$

234

 

Liabilities

 

 

 

 

 

 

 

 

Other current liabilities

 

$

 

 

 

5,614

 

Deferred revenue, current

 

 

 

 

 

789

 

Deferred revenue, non-current

 

 

 

 

 

3,106

 

Other liabilities

 

 

 

 

 

6,711

 

Total liabilities

 

$

 

 

$

16,220